West Pharmaceutical Services Inc. (WST) News

West Pharmaceutical Services Inc. (WST): $237.97

-6.38 (-2.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter WST News Items

WST News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

WST News Highlights

  • WST's 30 day story count now stands at 4.
  • Over the past 21 days, the trend for WST's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • WEST, DRUG and CPHI are the most mentioned tickers in articles about WST.

Latest WST News From Around the Web

Below are the latest news stories about WEST PHARMACEUTICAL SERVICES INC that investors may wish to consider to help them evaluate WST as an investment opportunity.

7 Dividend Stocks Set to Surge Higher in 2023

Dividend stocks are as smart a choice as ever given the economy's uncertain outlook.

Alex Sirois on InvestorPlace | November 21, 2022

West to Participate in Upcoming Investor Conferences

West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will participate in the Jefferies London Healthcare Conference in London, UK on Tuesday, November 15 at 3:50 PM GMT (11:50 AM ET).

Yahoo | November 4, 2022

West to Attend and Showcase Industry Leadership in Packaging and Containment at CPhI Worldwide Conference

West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced its participation at CPhI Worldwide in Frankfurt, Germany to showcase its leadership and expertise on industry challenges and trends in packaging and containment.

Yahoo | October 31, 2022

West Pharmaceutical Services' (NYSE:WST) earnings growth rate lags the 18% CAGR delivered to shareholders

The last three months have been tough on West Pharmaceutical Services, Inc. ( NYSE:WST ) shareholders, who have seen...

Yahoo | October 31, 2022

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), West Pharmaceutical Services (WST) and Argenx Se (ARGX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Edwards Lifesciences (EW – Research Report), West Pharmaceutical Services (WST – Research Report) and Argenx Se (ARGX – Research Report) with bullish sentiments. Edwards Lifesciences (EW) Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Edwards Lifesciences today and set a price target of $93.00. The company's shares closed last Thursday at $86.30, close to its 52-week low of $80.69. According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of -5.9% and a 38.4% success rate.

Howard Kim on TipRanks | October 28, 2022

Why West Pharmaceutical Services Stock Is Heading South Today

Shares of West Pharmaceutical Services (NYSE: WST) were down 11.7% as of 11:14 a.m. ET on Thursday. West reported Q3 net sales of $686.9 million, down 2.8% year over year. It now expects net sales will be between $2.83 billion and $2.84 billion compared to the previous forecast of $2.95 billion to $2.975 billion.

Yahoo | October 27, 2022

West Pharmaceutical (WST) Q3 Earnings Miss, FY22 View Revised

West Pharmaceutical's (WST) third-quarter results reflect sustained growth in non-COVID-19 demand amid dismal overall performance.

Yahoo | October 27, 2022

West Pharmaceutical Services (WST) Misses Q3 Earnings and Revenue Estimates

West Pharmaceutical (WST) delivered earnings and revenue surprises of -4.25% and 5.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | October 27, 2022

West Announces Third-Quarter 2022 Results, Updates Full-Year 2022 Guidance and Declares Fourth-Quarter 2022 Dividend

West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the third-quarter 2022 and updated full-year 2022 financial guidance.

Yahoo | October 27, 2022

Medical Device Stocks' Q3 Earnings on Oct 27: LH, BIO & More

Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how LH, BIO, BAX, DXCM and WST are likely to fare this time.

Yahoo | October 26, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6329 seconds.